ALLO - Company ID 0001737287
The table below shows Allogene Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.91M | -$52.93M | -$55.90M | -$66.64M | -$68.24M | -$49.33M |
| Capital expenditure | $9.00K | $99.00K | $8.00K | $1.03M | $1.90M | $6.46M |
| Investing cash flow | -$29.59M | $6.18M | $22.13M | $112.94M | -$22.38M | $96.80M |
| Dividends paid | - | - | - | - |
Allogene Therapeutics, Inc. reported operating cash flow of -$149.25M for fiscal year 2025. That is up 25.5% from -$200.30M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$44.65M (FY 2018) to -$149.25M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $21.12M | $13.99M | $1.65M | $1.73M | $1.81M | $6.04M |